188 related articles for article (PubMed ID: 32186774)
1. miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Huang T; Ren K; Ding G; Yang L; Wen Y; Peng B; Wang G; Wang Z
Oncol Rep; 2020 Jun; 43(6):1906-1914. PubMed ID: 32186774
[TBL] [Abstract][Full Text] [Related]
2. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
3. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
4. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
5. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
6. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
7. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
8. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
Sun B; Hu N; Cong D; Chen K; Li J
Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
[TBL] [Abstract][Full Text] [Related]
10. Investigating the role of let-7a microRNA in cisplatin sensitivity of A549 lung cancer cells.
Aslan ES; Aydin E
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3979-3984. PubMed ID: 37991541
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-218 regulates the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting BMI-1.
Xu L; Sun HB; Xu ZN; Han XL; Yin YY; Zheng Y; Zhao Y; Wang ZX
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7978-7988. PubMed ID: 31599423
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
13. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
14. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
[TBL] [Abstract][Full Text] [Related]
16. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
17. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Mao G; Mu Z; Wu DA
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
[TBL] [Abstract][Full Text] [Related]
18. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
19. Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway.
Yu M; Qi B; Xiaoxiang W; Xu J; Liu X
Biomed Pharmacother; 2017 Jun; 90():677-685. PubMed ID: 28415048
[TBL] [Abstract][Full Text] [Related]
20. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]